<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01045863</url>
  </required_header>
  <id_info>
    <org_study_id>B1651001</org_study_id>
    <nct_id>NCT01045863</nct_id>
  </id_info>
  <brief_title>To Evaluate Safety, Tolerability, Plasma Drug Levels And Other Biological Effects In Healthy Volunteers</brief_title>
  <official_title>A Phase 1, First-Into-Human, Escalating Dose Trial To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-03382792 After Administration Of Single Oral Doses To Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and tolerability after a single
      administration of PF-03382792 in healthy volunteers.; and to evaluate plasma drug levels and
      biological activity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluate the safety, tolerability, plasma concentrations of PF-03382792 and other biological
      activity following a single dose of PF-03382792. Three ascending single doses of PF-03382792
      were administered in this study (0.05 mg, 0.15mg and 0.5 mg). The decision to terminate the
      study was made on June 4, 2010 due to safety findings and limitations regarding the levels of
      the metabolite projected for doses above 0.5 mg.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    See termination reason in detailed description.
  </why_stopped>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety endpoints include evaluation: adverse events, change from baseline in vital signs, triplicate ECG (Part A only), singlet ECG for Parts B and C. 8 hours of cardiac telemetry postdose (Part A only).</measure>
    <time_frame>For cohorts in Part A, up to 24 days; for Cohorts in Part B, up to 17; for Part C, up to 10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Additional Safety endpoints: clinical safety laboratory endpoints, plasma cortisol and ACTH, clinical examinations, slit lamp examination.</measure>
    <time_frame>For cohorts in Part A, up to 24 days; for Cohorts in Part B, up to 17; for Part C, up to 10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic endpoints: plasma concentration of PF 03382792 over time (eg, AUC, Cmax, Tmax, t1/2), plasma concentration of PF 03227077 over time (eg, AUC, Cmax, Tmax, t1/2).</measure>
    <time_frame>up to 72 hours post the final dose for each cohort</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma aldosterone concentrations.</measure>
    <time_frame>For Part A and C; up to 24 hours post final dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and percent change from baseline in average CSF sAPP fragment concentrations over all postdose collection time points up to 8 hours. • CSF sAPP fragment concentrations over time. • CSF concentration of PF 03382792 and PF</measure>
    <time_frame>Part C only, up to 8 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>03227077 over time (eg, AUC, Cmax, Tmax).</measure>
    <time_frame>Part C only, up to 8 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PART A: Ascending Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending dose cross-over. (0.05, 0.15, 0.5, 1.5, 5, 15 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PART B: Food effect</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Food effect on PF-03382792 PK</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PART C: CSF Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optional CSF Cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-03382792 Cohort 1</intervention_name>
    <description>First cohort for: Single oral ascending dose of PF-03382792, formulated in solution.</description>
    <arm_group_label>PART A: Ascending Cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-03382792 Cohort 2</intervention_name>
    <description>Second cohort for: Single oral ascending dose of PF-03382792, formulated in solution.</description>
    <arm_group_label>PART A: Ascending Cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-03382792</intervention_name>
    <description>Optional cohort 3: Single oral ascending dose of PF-03382792, formulated in solution.</description>
    <arm_group_label>PART A: Ascending Cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Food Effect cohort</intervention_name>
    <description>Single oral dose, cross-over to determine effect of food on PF-03382792 pharmacokinetics. Dose will be decided after reviewing data from the ascending dose portion.</description>
    <arm_group_label>PART B: Food effect</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CSF cohort</intervention_name>
    <description>Single oral dose of PF-03382792 formulated in solution. Dose will be decided after reviewing data from the ascending dose portion.</description>
    <arm_group_label>PART C: CSF Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For all cohorts, healthy male and/or female subjects of nonchildbearing potential
             between the ages of 18 and 55 years, inclusive.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease.

          -  History of regular alcohol consumption exceeding 7 drinks/week for females or 14
             drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of
             beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of Screening.

          -  Signs or symptoms of adrenal insufficiency.

          -  Ocular lens (eye) abnormalities.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1651001&amp;StudyName=To%20Evaluate%20Safety%2C%20Tolerability%2C%20Plasma%20Drug%20Levels%20And%20Other%20Biological%20Effects%20In%20Healthy%20Volunteers</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2010</study_first_submitted>
  <study_first_submitted_qc>January 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2010</study_first_posted>
  <last_update_submitted>August 3, 2010</last_update_submitted>
  <last_update_submitted_qc>August 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>volunteer</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

